Protoporphyrin IX and verteporfin potently inhibit SARS-CoV-2 infection in vitro and in a mouse model expressing human ACE2
Chenjian Gu(Washington University in St. Louis), Youhua Xie(Shanghai Medical College of Fudan University), Zhong Huang(Shenzhen University), Qiang Deng(Kunming University of Science and Technology), Zhiping Sun(Shanghai Medical College of Fudan University), Wei Xu(Beijing Geriatric Hospital), Yuanfei Zhu(Shanghai Medical College of Fudan University), Zhenghong Yuan(Shanghai Medical College of Fudan University), Jing Liu(Tianjin University of Traditional Chinese Medicine), Rong Zhang(Huazhong Agricultural University), Yuyan Wang(Shanghai Medical College of Fudan University), Xia Cai(Fudan University), Di Qu(Xijing Hospital), Yang Wu(Shanghai Medical College of Fudan University), Yu Zhou(Yangtze University), Yutang Li(Shanghai Medical College of Fudan University), Huimin Guo(Shanghai Academy of Agricultural Sciences)
Cited by 59
Related Papers
Human Infection with a Novel Avian-Origin Influenza A (H7N9) Virus
|New England Journal of Medicine|2013|2.4k
Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion
|Cell Research|2020|1.4k
Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein
|Cellular and Molecular Immunology|2020|759
Receptor binding and complex structures of human ACE2 to spike RBD from omicron and delta SARS-CoV-2
|Cell|2022|538
Etiological and epidemiological features of acute respiratory infections in China
|Nature Communications|2021|530